Vistagen Therapeutics (VTGN) Return on Capital Employed (2017 - 2025)
Historic Return on Capital Employed for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to 1.18%.
- Vistagen Therapeutics' Return on Capital Employed fell 5700.0% to 1.18% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.18%, marking a year-over-year decrease of 5700.0%. This contributed to the annual value of 0.61% for FY2025, which is 1200.0% down from last year.
- Latest data reveals that Vistagen Therapeutics reported Return on Capital Employed of 1.18% as of Q4 2025, which was down 5700.0% from 1.07% recorded in Q3 2025.
- Vistagen Therapeutics' 5-year Return on Capital Employed high stood at 0.17% for Q1 2021, and its period low was 3.32% during Q2 2023.
- Moreover, its 5-year median value for Return on Capital Employed was 0.68% (2022), whereas its average is 0.99%.
- In the last 5 years, Vistagen Therapeutics' Return on Capital Employed skyrocketed by 51400bps in 2021 and then crashed by -22800bps in 2023.
- Vistagen Therapeutics' Return on Capital Employed (Quarter) stood at 0.42% in 2021, then crashed by -392bps to 2.06% in 2022, then soared by 80bps to 0.41% in 2023, then crashed by -46bps to 0.6% in 2024, then plummeted by -95bps to 1.18% in 2025.
- Its Return on Capital Employed stands at 1.18% for Q4 2025, versus 1.07% for Q3 2025 and 0.91% for Q2 2025.